53704-74-8

Upstream product

• 5438-19-7 4-propoxybenzoic acid 
• 186581-53-3 diazomethane 
• 40782-58-9 p-propoxybenzoyl chloride 

Downstream Products

• 69792-54-7 4-(4-propoxy-phenyl)-thiazole-2-carbothioic acid dimethylamide 
• 88675-33-6 2-Azepan-1-yl-1-(4-propoxy-phenyl)-ethanone 
• 88675-36-9 2-Diethylamino-1-(4-propoxy-phenyl)-ethanone 
• 130623-07-3 2-(4,5-Dihydro-1H-imidazol-2-ylsulfanyl)-1-(4-propoxy-phenyl)-ethanone; hydrobromide 
• 141134-42-1 2-(pyrid-2-on-1-yl)-4'-propoxyacetophenone 
• 1041166-81-7 4-methyl-3-(4-propoxyphenyl)-4H-1,4-benzothiazine 
• 1041166-77-1 3-(4-propoxyphenyl)-2H-1,4-benzothiazine 
• 14329-81-8 2-(4-propoxyphenyl)quinoxaline 
• 130623-29-9 3-(4-Propoxy-phenyl)-5,6-dihydro-imidazo[2,1-b]thiazole; hydrobromide 

Relevant academic research and scientific papers

Identification of Anti-Mycobacterial Biofilm Agents Based on the 2-Aminoimidazole Scaffold

Tuberculosis (TB) remains a significant global health problem for which new therapeutic options are sorely needed. The ability of the causative agent, Mycobacterium tuberculosis, to reside within host macrophages and form biofilm-like communities contributes to the persistent and drug-tolerant nature of the disease. Compounds that can prevent or reverse the biofilm-like phenotype have the potential to serve alongside TB antibiotics to overcome this tolerance, and decrease treatment duration. Using Mycobacterium smegmatis as a surrogate organism, we report the identification of two new 2-aminoimidazole compounds that inhibit and disperse mycobacterial biofilms, work synergistically with isoniazid and rifampicin to eradicate preformed M. smegmatis biofilms in vitro, are nontoxic toward Galleria mellonella, and exhibit stability in mouse plasma.

Pyrrole derivatives and medicinal composition

The invention relates to a pharmaceutical composition comprising a pyrrole derivative of the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate of either of them, as an active ingredient. STR1 (wherein R1 represents hydrogen or alkoxycar91 bonylamino, R2 represents alkyl, aryl which may be substituted, aromatic heterocyclyl which may be substituted, unsubstituted amino, monoalkylamino, dialkylamino, or cyclic amino which may be substituted; R3 represents cyano or carbamoyl; R4 represents hydrogen or alkyl; E represents alkylene; q is equal to 0 or 1, A represents methyl, aryl which may be substituted, or aromatic heterocyclyl which may be substituted). The pharmaceutical composition of the invention is effective for the treatment of pollakiuria or urinary incontinence.

Process for producing optically active carbinols

The present invention relates to a process for producing optically active halomethyl phenyl carbinols of the formula (1), comprising reducing halomethyl phenyl ketones of the formula (2) using an asymmetric reducing agent obtained from boranes and optically active α-phenyl-substituted-β-amino alcohols of the formula (3) or optically active α-non-substituted-β-amino alcohols of the formula (4). The present invention further relates to a process for producing optically active carbinols, comprising reacting a prochiral keytone with an asymmetric reducing agent obtained from optically active β-amino alcohols of the formula (5), a metal boron hydride and Lewis acid or lower dialkyl sulfuric acid. All of the formulas (1) to (5) are the same as shown in the specification.